The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Clinical Benefit of Islet Xenotransplantation for the Treatment of Type 1 Diabetes
Open accessAbstract
BACKGROUND: Allogeneic islet transplantation has become a viable option for the treatment of unstable type 1 diabetes. However, the donor shortage and the necessity of the immunosuppressive drugs are two major issues. To solve these issues, we performed islet xenotransplantation using encapsulated neonatal porcine islets without immunosuppressive drugs. METHODS: Two different doses (approximately 5000IEQ/kg and 10,000IEQ/kg) of encapsulated neonatal porcine islets were transplanted twice (total approximately 10,000IEQ/kg and 20,000IEQ/kg) into four type 1 diabetic patients in each group (total 8 patients). FINDINGS: In the higher dose group, all four patients improved HbA1c. This was maintained at a level of <7% for >600days with significant reduction of the frequency of unaware hypoglycemic events. INTERPRETATION: The clinical benefit of islet xenotransplantation with microencapsulation has been shown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoglycemia in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Research Group (1997) · Diabetes · doi:10.2337/diab.46.2.271 · Cited by 746
Cited by
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M., & Veiseh, O. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 439
The journey of islet cell transplantation and future development
Gamble, A., Pepper, A. R., Bruni, A., & Shapiro, A. M. J. (2018) · Islets · doi:10.1080/19382014.2018.1428511 · Cited by 171
Metadata
- Authors
- Matsumoto, S., Abalovich, A., Wechsler, C., Wynyard, S., & Elliott, R. B.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 12
- Pages
- 255-262
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2508555475
- Cited by
- 204
- References
- 1
- FWCI
- 25.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.